SUCCESFUL STEM CELL COLLECTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS OVER 65 YEARS OLD
(Abstract release date: 05/19/16)
EHA Library. ESCALANTE BARRIGON F. 06/09/16; 135078; PB2178
Dr. FERNANDO ESCALANTE BARRIGON
Contributions
Contributions
Abstract
Abstract: PB2178
Type: Publication Only
Background
High-dose therapy plus autologous stem cell transplantation (ASCT) is considered the standard of care for front-line treatment of younger patients with newly diagnosed multiple myeloma (NDMM)
Eligibility for this procedure are based in almost all health institutions on chronological age more than on biological or functional age.
Aims
Retrospective analysis of characteristics of the mobilisation and collection procedures of NDMM ASCT-candidates patients from 2009 to 2014 comparing 2 groups of age: under vs over 65 years old.
Methods
54 mobilization and apheresis procedures were analysed.
36 patients were under-65y (median 57y, range 48-65y) and 18 in over-65y (median 68y, range 66-71y)
Induction Regimen were Bortezomib-based schemes in 50 of 54 patients and 4 received chemotherapy-based scheme before collecting Peripheral Blood Stem Cell (PBSC).
PBSC collection was programmed after -at least- 3rd induction cycle.
The virtual absence of failures of collection with Bor-Based schemes have permitted us to program mobilisation at any time of induction phase, even after the last cycle, without any complications or
failures on the collection.
Almost all patients were mobilized with granulocyte colony stimulating factors (G-CSF) alone.Only 1 patient was mobilized with cyclophosphamide and GCSF.
Plerixafor was added in predifined by CD34 account poor mobilizers.
Results
G-CSF doses administered was different between the 2 groups of age: group under-65y received a median dose of 10 mcg/Kg/24 hours and the over-65y group a median dose of 10 mcg/Kg/12 hours.
Median days of GCSF administration was similar: 5 days.
There were no differences on mobilisation failure and / or on the indication of plerixafor administration (7/36 vs 2/18, p=ns)
The number of aphaeresis needed to reach the CD34 target was similar: median= 1 (range: 1-3).
The amount of CD34 cells collected was similar, with no statistical difference: median of 6.35 (2.5-17.67) vs 5.8 (2.6-11.6) x 10E6 CD34 / kg cells between groups.
There were no differences in complications after the procedure (bleeding, readmissions ...) between groups.
There were no differences in terms of safety and engraftment of ASCT between groups.
Conclusion
Mobilisation and collection of PBSC in NDMM over-65y patients with current induction schemes is
feasible and without differences in terms of efficacy and safety (number apheresis, number of harvested cells, need of plerixafor …) compared with under-65y group.
New induction Bor-Based schemes have a good profile in terms of mobilisation and collection of PBSC, independently of the age
Age “per se” is not a restriction to collect stem cells to support an ASCT.
Session topic: E-poster
Keyword(s): Autologous stem cell collection, Elderly, Multiple myeloma
Type: Publication Only
Background
High-dose therapy plus autologous stem cell transplantation (ASCT) is considered the standard of care for front-line treatment of younger patients with newly diagnosed multiple myeloma (NDMM)
Eligibility for this procedure are based in almost all health institutions on chronological age more than on biological or functional age.
Aims
Retrospective analysis of characteristics of the mobilisation and collection procedures of NDMM ASCT-candidates patients from 2009 to 2014 comparing 2 groups of age: under vs over 65 years old.
Methods
54 mobilization and apheresis procedures were analysed.
36 patients were under-65y (median 57y, range 48-65y) and 18 in over-65y (median 68y, range 66-71y)
Induction Regimen were Bortezomib-based schemes in 50 of 54 patients and 4 received chemotherapy-based scheme before collecting Peripheral Blood Stem Cell (PBSC).
PBSC collection was programmed after -at least- 3rd induction cycle.
The virtual absence of failures of collection with Bor-Based schemes have permitted us to program mobilisation at any time of induction phase, even after the last cycle, without any complications or
failures on the collection.
Almost all patients were mobilized with granulocyte colony stimulating factors (G-CSF) alone.Only 1 patient was mobilized with cyclophosphamide and GCSF.
Plerixafor was added in predifined by CD34 account poor mobilizers.
Results
G-CSF doses administered was different between the 2 groups of age: group under-65y received a median dose of 10 mcg/Kg/24 hours and the over-65y group a median dose of 10 mcg/Kg/12 hours.
Median days of GCSF administration was similar: 5 days.
There were no differences on mobilisation failure and / or on the indication of plerixafor administration (7/36 vs 2/18, p=ns)
The number of aphaeresis needed to reach the CD34 target was similar: median= 1 (range: 1-3).
The amount of CD34 cells collected was similar, with no statistical difference: median of 6.35 (2.5-17.67) vs 5.8 (2.6-11.6) x 10E6 CD34 / kg cells between groups.
There were no differences in complications after the procedure (bleeding, readmissions ...) between groups.
There were no differences in terms of safety and engraftment of ASCT between groups.
Conclusion
Mobilisation and collection of PBSC in NDMM over-65y patients with current induction schemes is
feasible and without differences in terms of efficacy and safety (number apheresis, number of harvested cells, need of plerixafor …) compared with under-65y group.
New induction Bor-Based schemes have a good profile in terms of mobilisation and collection of PBSC, independently of the age
Age “per se” is not a restriction to collect stem cells to support an ASCT.
Session topic: E-poster
Keyword(s): Autologous stem cell collection, Elderly, Multiple myeloma
Abstract: PB2178
Type: Publication Only
Background
High-dose therapy plus autologous stem cell transplantation (ASCT) is considered the standard of care for front-line treatment of younger patients with newly diagnosed multiple myeloma (NDMM)
Eligibility for this procedure are based in almost all health institutions on chronological age more than on biological or functional age.
Aims
Retrospective analysis of characteristics of the mobilisation and collection procedures of NDMM ASCT-candidates patients from 2009 to 2014 comparing 2 groups of age: under vs over 65 years old.
Methods
54 mobilization and apheresis procedures were analysed.
36 patients were under-65y (median 57y, range 48-65y) and 18 in over-65y (median 68y, range 66-71y)
Induction Regimen were Bortezomib-based schemes in 50 of 54 patients and 4 received chemotherapy-based scheme before collecting Peripheral Blood Stem Cell (PBSC).
PBSC collection was programmed after -at least- 3rd induction cycle.
The virtual absence of failures of collection with Bor-Based schemes have permitted us to program mobilisation at any time of induction phase, even after the last cycle, without any complications or
failures on the collection.
Almost all patients were mobilized with granulocyte colony stimulating factors (G-CSF) alone.Only 1 patient was mobilized with cyclophosphamide and GCSF.
Plerixafor was added in predifined by CD34 account poor mobilizers.
Results
G-CSF doses administered was different between the 2 groups of age: group under-65y received a median dose of 10 mcg/Kg/24 hours and the over-65y group a median dose of 10 mcg/Kg/12 hours.
Median days of GCSF administration was similar: 5 days.
There were no differences on mobilisation failure and / or on the indication of plerixafor administration (7/36 vs 2/18, p=ns)
The number of aphaeresis needed to reach the CD34 target was similar: median= 1 (range: 1-3).
The amount of CD34 cells collected was similar, with no statistical difference: median of 6.35 (2.5-17.67) vs 5.8 (2.6-11.6) x 10E6 CD34 / kg cells between groups.
There were no differences in complications after the procedure (bleeding, readmissions ...) between groups.
There were no differences in terms of safety and engraftment of ASCT between groups.
Conclusion
Mobilisation and collection of PBSC in NDMM over-65y patients with current induction schemes is
feasible and without differences in terms of efficacy and safety (number apheresis, number of harvested cells, need of plerixafor …) compared with under-65y group.
New induction Bor-Based schemes have a good profile in terms of mobilisation and collection of PBSC, independently of the age
Age “per se” is not a restriction to collect stem cells to support an ASCT.
Session topic: E-poster
Keyword(s): Autologous stem cell collection, Elderly, Multiple myeloma
Type: Publication Only
Background
High-dose therapy plus autologous stem cell transplantation (ASCT) is considered the standard of care for front-line treatment of younger patients with newly diagnosed multiple myeloma (NDMM)
Eligibility for this procedure are based in almost all health institutions on chronological age more than on biological or functional age.
Aims
Retrospective analysis of characteristics of the mobilisation and collection procedures of NDMM ASCT-candidates patients from 2009 to 2014 comparing 2 groups of age: under vs over 65 years old.
Methods
54 mobilization and apheresis procedures were analysed.
36 patients were under-65y (median 57y, range 48-65y) and 18 in over-65y (median 68y, range 66-71y)
Induction Regimen were Bortezomib-based schemes in 50 of 54 patients and 4 received chemotherapy-based scheme before collecting Peripheral Blood Stem Cell (PBSC).
PBSC collection was programmed after -at least- 3rd induction cycle.
The virtual absence of failures of collection with Bor-Based schemes have permitted us to program mobilisation at any time of induction phase, even after the last cycle, without any complications or
failures on the collection.
Almost all patients were mobilized with granulocyte colony stimulating factors (G-CSF) alone.Only 1 patient was mobilized with cyclophosphamide and GCSF.
Plerixafor was added in predifined by CD34 account poor mobilizers.
Results
G-CSF doses administered was different between the 2 groups of age: group under-65y received a median dose of 10 mcg/Kg/24 hours and the over-65y group a median dose of 10 mcg/Kg/12 hours.
Median days of GCSF administration was similar: 5 days.
There were no differences on mobilisation failure and / or on the indication of plerixafor administration (7/36 vs 2/18, p=ns)
The number of aphaeresis needed to reach the CD34 target was similar: median= 1 (range: 1-3).
The amount of CD34 cells collected was similar, with no statistical difference: median of 6.35 (2.5-17.67) vs 5.8 (2.6-11.6) x 10E6 CD34 / kg cells between groups.
There were no differences in complications after the procedure (bleeding, readmissions ...) between groups.
There were no differences in terms of safety and engraftment of ASCT between groups.
Conclusion
Mobilisation and collection of PBSC in NDMM over-65y patients with current induction schemes is
feasible and without differences in terms of efficacy and safety (number apheresis, number of harvested cells, need of plerixafor …) compared with under-65y group.
New induction Bor-Based schemes have a good profile in terms of mobilisation and collection of PBSC, independently of the age
Age “per se” is not a restriction to collect stem cells to support an ASCT.
Session topic: E-poster
Keyword(s): Autologous stem cell collection, Elderly, Multiple myeloma
{{ help_message }}
{{filter}}